[Intravitreal implantation of Ozurdex® chronic delivery system for management of macular edema related to retinitis pigmentosa: case report].

Retinitis pigmentosa denotes a heterogeneous group of rare genetic diseases in which both rods and cones eye are damaged. It is a disease of poor prognosis. We describe the case of a 22 years old woman successfully treated with intravitreal implant of dexamentasone (OZURDEX®, Allergan, USA) for the treatment of macular edema due to retinitis pigmentosa.

[Epidemiologic profile and level of knowledge among diabetic patients about diabetes and diabetic retinopathy].

Purpose: To assess the epidemiologic profile and level of knowledge of diabetic patients about diabetes and diabetic retinopathy (DR).

Methods: Cross-sectional study with patients seen at Retina and Vitreous sector of Hospital do Servidor Público Estadual de São Paulo. The subjects were assigned into two groups: diabetic patients sent for first ophthalmologic evaluation (G1) and patient already followed in the sector (G2).

[Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone].

Purpose: To evaluate the effect of intravitreal triamcinolone acetonide in patients with diffuse diabetic macular edema on the visual acuity and intraocular pressure. To report the potential adverse events and to analyze the potential relationship between age and visual acuity and intraocular pressure variability.

Methods: This clinical controlled study included 14 patients (28 eyes), 14 of the eyes received an intravitreal injection of 4 mg triamcinolone acetonide for the treatment of diabetic macular edema.